Globus Medical (NYSE:GMED) Sets New 1-Year Low – Time to Sell?

Globus Medical, Inc. (NYSE:GMED – Get Free Report) reached a new 52-week low on Monday. The company traded as low as $70.14 and last traded at $70.3250, with a volume of 403,238 shares traded. The stock had previously closed at $72.14.

Analysts Set New Price Targets

Several brokerages have issued reports on GMED. Needham & Company LLC dropped their target price on Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a report on Friday, November 6th. Royal Bank Of Canada lowered their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, October 1st. Wall Street Zen cut shares of Globus Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Finally, Truist Financial dropped their price target on shares of Globus Medical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $96.08.

Read Our Latest Research Report on Globus Medical

Globus Medical Stock Performance

The stock has a market cap of $9.34 billion, a PE ratio of 17.29, a PEG ratio of 1.12 and a beta of 0.98. The business has a 50-day moving average of $76.56 and a 200 day moving average of $82.71.

Globus Medical (NYSE:GMED – Get Free Report) last released its earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. Globus Medical had a return on equity of 14.43% and a net margin of 17.76%. The firm had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. During the same period in the prior year, the firm posted $1.18 earnings per share. The business’s quarterly revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts expect that Globus Medical, Inc. will post 4.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other Globus Medical news, Director Ann Rhoads sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares in the company, valued at $3,007,640. The trade was a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James R. Tobin sold 41,666 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $75.16, for a total value of $3,131,616.56. Following the sale, the director owned 15,000 shares in the company, valued at approximately $1,127,400. The trade was a 73.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 101,666 shares of company stock worth $7,970,017 over the last ninety days. 18.38% of the stock is owned by company insiders.

Hedge Funds Weigh In On Globus Medical

Several large investors have recently added to or reduced their stakes in GMED. Elevation Wealth Partners LLC lifted its holdings in Globus Medical by 2,178.6% in the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after acquiring an additional 305 shares during the last quarter. Continuum Advisory LLC bought a new stake in shares of Globus Medical during the 2nd quarter worth $25,000. Root Financial Partners LLC purchased a new position in shares of Globus Medical in the third quarter worth approximately $29,000. Heritage Family Offices LLP purchased a new position in shares of Globus Medical during the third quarter valued at $31,000. Finally, Jacobi Capital Management LLC acquired a new position in Globus Medical in the 3rd quarter valued at approximately $40,000. 95.16% of the stock is currently owned by institutional investors.

About Globus Medical

(Get Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Read More

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.